”This is the theragnostic breakthrough” – with Oliver Sartor, Bernd Krause and Ken Hermann

We gathered up with Oliver Sartor, Bernd Krause and Ken Hermann, co-authors of the VISION study, to talk about how it will impact the treatment of prostate cancer. The VISION study is the first international randomized open label phase III study that shows convincing results for a novel treatment of late-stage advanced prostate cancer. A targeted treatment for prostate cancer using radioactive 177Lu-PSMA-617. Successful? Without a doubt if you ask Oliver Sartor.

– This is the theragnostic breakthrough we all have been waiting for. It's going to change the way we treat cancer.

Join us on Theragnostic Talks!

 

Guest: Oliver Sartor, Bernd Krause, Ken Hermann
By: Gustav Widar
Contact us: podcast@samnordic.se
For more info, visit www.samnordic.se